Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells (Q37725751)

22 August 2017

1 reference

title

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells (English)

1 reference

22 August 2017

1 reference

John Maher

2

0 references

author name string

David Marc Davies

series ordinal

1

1 reference

22 August 2017

publication date

6 April 2010

1 reference

Archivum Immunologiae et Therapiae Experimentalis

22 August 2017

published in

1 reference

22 August 2017

volume

58

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

165-178

1 reference

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

Defective Major Histocompatibility Complex Class I Expression in a Sarcomatoid Renal Cell Carcinoma Cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-010-0074-1

10.1007/S00005-010-0074-1

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference